181 related articles for article (PubMed ID: 31982178)
1. Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.
Havrilesky LJ; Lim S; Ehrisman JA; Lorenzo A; Alvarez Secord A; Yang JC; Johnson FR; Gonzalez JM; Reed SD
Gynecol Oncol; 2020 Mar; 156(3):561-567. PubMed ID: 31982178
[TBL] [Abstract][Full Text] [Related]
2. The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens.
Havrilesky LJ; Scott AL; Davidson BA; Secord AA; Yang JC; Johnson FR; Gonzalez JM; Reed SD
Gynecol Oncol; 2021 Aug; 162(2):440-446. PubMed ID: 34053748
[TBL] [Abstract][Full Text] [Related]
3. Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer.
Stone RL; Cambron-Mellott MJ; Beusterien K; Maculaitis MC; Ritz S; Mulvihill E; Monberg M; Szamreta EA; Amin S; McLaurin K
Future Oncol; 2022 Feb; 18(4):491-503. PubMed ID: 34875854
[TBL] [Abstract][Full Text] [Related]
4. Patient preferences in advanced or recurrent ovarian cancer.
Havrilesky LJ; Alvarez Secord A; Ehrisman JA; Berchuck A; Valea FA; Lee PS; Gaillard SL; Samsa GP; Cella D; Weinfurt KP; Abernethy AP; Reed SD
Cancer; 2014 Dec; 120(23):3651-9. PubMed ID: 25091693
[TBL] [Abstract][Full Text] [Related]
5. FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.
Ison G; Howie LJ; Amiri-Kordestani L; Zhang L; Tang S; Sridhara R; Pierre V; Charlab R; Ramamoorthy A; Song P; Li F; Yu J; Manheng W; Palmby TR; Ghosh S; Horne HN; Lee EY; Philip R; Dave K; Chen XH; Kelly SL; Janoria KG; Banerjee A; Eradiri O; Dinin J; Goldberg KB; Pierce WF; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R
Clin Cancer Res; 2018 Sep; 24(17):4066-4071. PubMed ID: 29650751
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer.
Gonzalez R; Havrilesky LJ; Myers ER; Secord AA; Dottino JA; Berchuck A; Moss HA
Gynecol Oncol; 2020 Nov; 159(2):483-490. PubMed ID: 32863036
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Mirza MR; Benigno B; Dørum A; Mahner S; Bessette P; Barceló IB; Berton-Rigaud D; Ledermann JA; Rimel BJ; Herrstedt J; Lau S; du Bois A; Herráez AC; Kalbacher E; Buscema J; Lorusso D; Vergote I; Levy T; Wang P; de Jong FA; Gupta D; Matulonis UA
Gynecol Oncol; 2020 Nov; 159(2):442-448. PubMed ID: 32981695
[TBL] [Abstract][Full Text] [Related]
9. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
Moore KN; Mirza MR; Matulonis UA
Gynecol Oncol; 2018 Apr; 149(1):214-220. PubMed ID: 29397193
[TBL] [Abstract][Full Text] [Related]
10. Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV).
Rohr I; Alavi S; Richter R; Keller M; Chekerov R; Oskay-Özcelik G; Heinrich M; Taskiran C; Joly F; Berger R; du Bois A; Gornjec A; Vergote I; Achimas-Cadariu P; Lorusso D; Maenpaa J; Sehouli J
Int J Gynecol Cancer; 2020 Apr; 30(4):509-514. PubMed ID: 32139438
[TBL] [Abstract][Full Text] [Related]
11. Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.
Matulonis UA; Walder L; Nøttrup TJ; Bessette P; Mahner S; Gil-Martin M; Kalbacher E; Ledermann JA; Wenham RM; Woie K; Lau S; Marmé F; Casado Herraez A; Hardy-Bessard AC; Banerjee S; Lindahl G; Benigno B; Buscema J; Travers K; Guy H; Mirza MR
J Clin Oncol; 2019 Dec; 37(34):3183-3191. PubMed ID: 31518175
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.
Guy H; Walder L; Fisher M
Pharmacoeconomics; 2019 Mar; 37(3):391-405. PubMed ID: 30478649
[TBL] [Abstract][Full Text] [Related]
13. Maintenance Therapy in the Treatment of Recurrent Epithelial Ovarian Cancer.
Gnade C; McDonald ME
Clin Obstet Gynecol; 2020 Mar; 63(1):86-91. PubMed ID: 31855903
[TBL] [Abstract][Full Text] [Related]
14. Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?
Berchuck A; Secord AA; Moss HA; Havrilesky LJ
J Clin Oncol; 2017 Dec; 35(36):3999-4002. PubMed ID: 29072978
[No Abstract] [Full Text] [Related]
15. Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
Tomao F; Bardhi E; Di Pinto A; Sassu CM; Biagioli E; Petrella MC; Palaia I; Muzii L; Colombo N; Panici PB
Cancer Treat Rev; 2019 Nov; 80():101909. PubMed ID: 31629204
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
[TBL] [Abstract][Full Text] [Related]
17. Comparison of PARPis with Angiogenesis Inhibitors and Chemotherapy for Maintenance in Ovarian Cancer: A Network Meta-Analysis.
Feng Y; Huang H; Wan T; Zhang C; Tong C; Liu J
Adv Ther; 2019 Dec; 36(12):3368-3380. PubMed ID: 31599396
[TBL] [Abstract][Full Text] [Related]
18. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
Wu L; Zhong L
J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378
[TBL] [Abstract][Full Text] [Related]
19. Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer.
Havrilesky LJ; Yang JC; Lee PS; Secord AA; Ehrisman JA; Davidson B; Berchuck A; Darcy KM; Maxwell GL; Reed SD
Cancer; 2019 Dec; 125(24):4399-4406. PubMed ID: 31454432
[TBL] [Abstract][Full Text] [Related]
20. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
Poveda AM; Davidson R; Blakeley C; Milner A
Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]